Drugs /
tak-676
Back to Drugs List
Overview
NCI Definition [1]:
An agonist of the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential immunoactivating and antineoplastic activities. Upon intravenous administration, STING agonist TAK-676 targets and binds to STING and activates the STING pathway in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs), enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs), and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system.
Clinical Trials
Tak-676 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating tak-676, 1 is phase 1 (1 open).
Malignant solid tumor is the most common disease being investigated in tak-676 clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
